LUND, Sweden, Sept. 2, 2021 /PRNewswire/ -- Alligator
Bioscience AB ("Alligator" or the "Company")
today announces that the Company, in order to enable further
progress, will begin evaluating potential financing alternatives,
which may include issuance of equity. Alligator's board has
appointed financial advisors and the Company has received support
from certain of the Company's largest shareholders for continued
funding of the Company.
To give Alligator's new and experienced management team the
right opportunities to develop the Company, the Board's current
assessment is that working capital will need to be strengthened in
order to enable phase II studies for Mitazalimab, phase II
preparations for ATOR-1017 as well as the development of other
pipeline candidates and general corporate purposes. The Company
will now continue dialogues with relevant stakeholders, evaluate
its available funding alternatives, and revert to the market with
more information in due course.
For further information, please contact:
Søren Bregenholt, CEO
Phone: +46 46-540 82 00
E-mail: sbr@alligatorbioscience.com
Julie Silber, Investor
Relations
Phone: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
This information is such information as Alligator Bioscience
AB (publ) is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through
the agency of the contact persons set out above, at 12:00 p.m. CEST on September 2, 2021.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
The pipeline includes two clinical assets: mitazalimab, a CD40
agonist, and ATOR-1017, a 4-1BB agonist. Alligator Bioscience is
co-developing ALG.APV-527 with Aptevo Therapeutics Inc. and an
undisclosed molecule based on its proprietary Neo-X-Prime™
technology platform with MacroGenics Inc. Outlicensed programs
include AC101 in clinical development by Shanghai Henlius Biotech
Inc. and an undisclosed target to Biotheus Inc. Alligator
Bioscience's shares are listed on Nasdaq Stockholm (ATORX).
Alligator is headquartered in Lund,
Sweden. For more information, please visit
http://www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-is-exploring-financing-alternatives-to-support-phase-ii-studies-for-mitazalimab--phase-ii-,c3408868
The following files are available for download:
|
https://mb.cision.com/Main/12681/3408868/1463459.pdf
|
Release
|